Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $515.03, generating approximately $4.89 million. She retained 324,443 shares valued at about $167.1 million.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of forecasts and declined 1.9% year over year.
- Analysts maintain a consensus “Moderate Buy” rating with a $646 target price, and institutional investors own 94.08% of the company’s shares.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $515.03, for a total value of $4,892,785.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,097,878.29. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
United Therapeutics Price Performance
NASDAQ UTHR opened at $501.27 on Friday. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35. The firm has a market cap of $21.50 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 1.73 and a beta of 0.59. The company has a fifty day moving average price of $536.95 and a 200-day moving average price of $535.97.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the firm earned $6.41 earnings per share. The firm's revenue was down 1.9% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Corporation will post 26.32 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
UTHR has been the subject of a number of research analyst reports. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America lowered their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Finally, Royal Bank Of Canada cut their price target on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.
Check Out Our Latest Stock Report on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of UTHR. BlackRock Inc. purchased a new stake in United Therapeutics in the second quarter worth $2,868,735,000. Wellington Management Group LLP grew its stake in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Norges Bank purchased a new stake in United Therapeutics in the 4th quarter worth about $293,418,000. Avoro Capital Advisors LLC increased its holdings in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock valued at $387,801,000 after acquiring an additional 341,383 shares during the period. 94.08% of the stock is owned by institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
